Study of Outcomes in Low-Risk Endometrial Cancer Patients with Isolated Tumor Cells in Sentinel Lymph Nodes
A Prospective Multicenter Observational Study
Led by Mayo Clinic · Updated on 2026-02-19
212
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with low-risk endometrial uterine cancer to understand if isolated tumor cells ITC found in the first lymph nodes near the tumor can provide important information about the patients future, especially regarding disease recurrence. This observational study compares patients with ITC in sentinel lymph nodes to historical patients with negative sentinel lymph nodes to evaluate differences in recurrence likelihood.
Participants do not receive any new treatments as this is a non-interventional study. Patients undergo tissue sample collection and have their medical records reviewed as part of the study procedures. The study focuses on patients who have undergone complete surgical staging including pelvic sentinel lymph node biopsy and ultrastaging, with no additional treatment after surgery.
During the study, researchers will monitor recurrence-free survival for up to five years along with other outcomes such as non-vaginal recurrence-free survival and overall survival. Participants medical data and tissue samples are collected for analysis. The study is expected to last several years, with ongoing review of patient outcomes and safety measures throughout the observation period.
CONDITIONS
Brief Title
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
Research Team
C
Clinical Trials Referral Office
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with low-risk endometrial cancer, defined as endometrioid, grade 1 or 2, FIGO 2009 stage IA (including FIGO 2023 stages IA1 and IA2) without substantial/extensive lymphovascular space invasion (LVSI) involving 5 or more vessels at final pathology
Patients with focal LVSI involving fewer than 5 vessels are eligible
Complete surgical staging performed, including pelvic sentinel lymph node biopsy per NCCN guidelines and ultrastaging
Isolated tumor cells (ITC) present in sentinel lymph nodes, defined as tumor cell aggregates 0.2 mm or smaller or fewer than 200 cells
No adjuvant treatment planned after surgery
Provided research consent
You will not qualify if you...
Prior neoadjuvant chemotherapy
Planning to receive adjuvant treatment after surgery
Presence of synchronous cancer other than non-melanoma skin cancer
Sentinel lymph node disease showing micrometastasis (greater than 0.2 mm up to 2.0 mm) or macrometastasis (greater than 2.0 mm)
Substantial/extensive LVSI involving 5 or more vessels at final pathology
Prior invasive cancer diagnosis within 5 years before study entry, excluding non-melanoma skin cancer
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - Up to 5 years
Participants who have undergone surgery are observed through tissue sample collection and medical record review to evaluate disease recurrence and survival outcomes.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Outcomes of low-risk endometrial cancer with isolated tumor cells in the sentinel lymph nodes: a prospective, multi-center, single-arm, observational study (ENDO-ITC study).
Luigi A De Vitis, Giorgio Bogani, Francesco Raspagliesi...